Angiovit

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Angiovit

Quick Facts

Property Description
Active Ingredients Folic acid (B9), Pyridoxine (B6), Cyanocobalamin (B12)
Form Oral Tablet (Film-coated tablet)
Pharmacological Class Multivitamin complex, Metabolic agent
Common Use Supports metabolic health and normal homocysteine levels
Origin Synthetic preparation

What Type of Medicine is Angiovit?

Angiovit is defined as a specialized Multivitamin complex belonging to the Vitamin B complex pharmacological class, supplied as a combination product. This preparation is classified as a metabolic agent because its principal function is to support essential biochemical transformations within the body. It is typically supplied as an oral tablet (a film-coated tablet) and is often an over-the-counter (OTC) preparation in many jurisdictions. The drug is often associated with the Russian manufacturer, Pharmstandard. The formulation's deliberate focus on specific B-vitamins distinguishes it from general nutritional supplements, underscoring its targeted role in specific cellular processes, a principle clinically recognized in nutritional medicine.


Composition: The Role of B-Vitamins B6, B9, and B12

The active ingredients in Angiovit are three specific B-vitamins: Pyridoxine hydrochloride (Vitamin B6), Folic acid (Vitamin B9), and Cyanocobalamin (Vitamin B12). Angiovit is strictly a combination product because it unites these three essential nutrients in a single tablet to leverage their synergistic relationship in metabolic pathways. These compounds are water-soluble vitamins, and alongside the active components, the tablets contain standard pharmaceutical excipients necessary for stable formulation and efficient oral delivery.


General Purpose and Metabolic Focus

The general purpose of Angiovit is to prevent or correct deficiencies of the three included B vitamins and to support specific essential metabolic processes. The unique combination is highly relevant to the metabolism of homocysteine, an amino acid intermediate. These B-vitamins act as crucial cofactors to help the body convert homocysteine into less potentially harmful compounds, thereby contributing to the maintenance of general circulatory and vascular health. Pharmacological data indicates the importance of these three vitamins working together in regulating plasma homocysteine levels. This scientific data confirms that the preparation's primary function is to support a key metabolic balance within the body.

Regulatory References

  1. NIH Office of Dietary Supplements: Folate

What side effects are possible with Angiovit?

Possible Side Effects and Safety Information

The official safety documentation for this B-vitamin combination (Folic acid, Pyridoxine, and Cyanocobalamin) is structured around potential systemic risks and specific constraints related to diagnostic safety, rather than common adverse reactions. The safety profile encompasses reactions classified by their effect on body systems, duration of exposure, and specific population risk factors.

Official Adverse Reactions and Safety Concerns

The regulatory labeling documents potential for allergic reactions including generalized rash, itching, and, rarely, severe systemic events such as anaphylaxis or swelling of the face and throat. Less severe effects listed include mild transient diarrhea and transitory skin rash.

Serious Adverse Reactions officially noted include pulmonary edema and congestive heart failure, which have been reported early in treatment when Cyanocobalamin is initiated for severe megaloblastic anemia.

Duration- and Population-Related Safety

Neurological effects such as peripheral neuropathy (tingling or numbness) are associated with the long-term intakes or high doses of Pyridoxine (Vitamin B6). This signals a dose- and duration-dependent pattern.

A critical safety restriction is that the Folic acid component can mask the diagnosis of underlying Vitamin B12 deficiency (pernicious anemia). By improving blood symptoms, it may allow irreversible neurological damage to continue progressing unnoticed. Furthermore, Cyanocobalamin is generally contraindicated in individuals with Leber's disease due to the documented risk of severe optic atrophy.

These official safety statements define the boundaries of the medicine's risk profile, focusing on rare but clinically significant events and important diagnostic limitations.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for this combination of Folic Acid, Pyridoxine, and Cyanocobalamin is structured around specific risks associated with high exposure rather than acute toxicity reports for the combined product at recommended doses. Regulatory documents generally state that no specific data is available on the signs and symptoms of overdosage when the product is taken at its advised level.


Potential Severe Outcomes and Required Actions

The primary documented severe risk is linked to the Folic Acid (B9) component. Daily doses exceeding 0.1 mg may result in hematologic remission in individuals with undiagnosed Vitamin B12 deficiency. By masking this deficiency, the neurological manifestations may be allowed to progress, leading to irreversible damage to the spinal cord, a key regulatory concern. Chronic high intake of the Pyridoxine (B6) component is also associated with peripheral neuropathies.


Management generally involves the withdrawal of the vitamin and the provision of symptomatic and supportive treatment, as no specific antidote is described in regulatory information. If the recommended dosage is exceeded or an accidental overdosage occurs, it is an explicit regulatory instruction to consult a doctor or seek immediate professional assistance.

Therapeutic Uses of Angiovit

What Angiovit Treats: Main Uses and Benefits

The medication is considered relevant for managing a metabolic risk factor associated with cardiovascular health. Angiovit is commonly used to help with conditions marked by systemic imbalance, targeting high homocysteine levels. It is applied directly to address hyperhomocysteinemia, a key metabolic factor. This therapeutic area involves supportive management in situations where patients experience risks associated with thrombosis, stroke, and myocardial infarction. High homocysteine can be a sign of B vitamin deficiency and has been linked to an increased risk of blood vessel disorders. This support contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Quick Fact: Focus on Systemic Discomfort

In addition to its role in long-term risk management, the medication may be part of symptomatic management and is considered relevant in clinical settings where a patient is experiencing certain infectious diseases. This supportive use is relevant for easing symptoms related to systemic imbalance, such as fever, and contributes to improved comfort during periods of heightened symptoms.

Regulatory References

  1. NIH MedlinePlus overview on the Homocysteine Test

Eligibility and Restrictions for Use

The eligibility for using Angiovit is strictly determined by regulatory rules that define who is permitted to use the medicine and who is formally excluded based on age, allergy, or clinical conditions.

Eligibility Scope

Eligibility Classification Rule Based on Official Labeling
Populations Allowed Adults and adolescents (ge 18 years of age) who require B-vitamin supplementation for metabolic support, such as managing high homocysteine levels.
Populations Contraindicated Individuals with confirmed hypersensitivity to Folic acid ( B9), Pyridoxine ( B6), Cyanocobalamin ( B12), or any other tablet component.
Age-Related Exclusion Use is not recommended or contraindicated in children under 3 years of age due to insufficient data on safety and efficacy in this young pediatric population.

Eligibility-Related Restrictions

  • Anemia Restriction: The medicine is restricted in patients with undiagnosed or confirmed B12-deficiency megaloblastic anemia. This rule exists because the Folic acid component can mask the hematological symptoms of the B12 deficiency, allowing potential irreversible neurological damage to advance unchecked.
  • Pregnancy and Lactation: Use is generally permitted during both pregnancy and breastfeeding but must be undertaken only with the advice and supervision of a physician.

What should I know about interactions with other medicines?

The official interaction profile for Angiovit, a combination of Folic acid (B9), Pyridoxine (B6), and Cyanocobalamin (B12), details specific interactions concerning therapeutic antagonism and altered drug levels or vitamin absorption.

Pharmacodynamic and Concentration Interactions

  • Anticonvulsants (e.g., Phenytoin, Phenobarbital, Primidone): Folic acid is documented to antagonize the action of certain anticonvulsants, potentially lessening their intended effect. Conversely, Pyridoxine (B6) can decrease the plasma concentrations of certain anticonvulsants.
  • Levodopa: Pyridoxine (B6) is documented to antagonize the therapeutic effect of Levodopa when the latter is administered without a decarboxylase inhibitor (like Carbidopa).
  • Increased Vitamin Requirement: Medicines such as Isoniazid, Penicillamine, and Oral Contraceptives are officially noted to increase the body's requirements for Pyridoxine (B6).

Absorption and Substance Interactions

  • Gastrointestinal Absorption: Drugs like Histamine H2-Receptor Antagonists (e.g., Cimetidine, Ranitidine) and Proton Pump Inhibitors (PPIs) (e.g., Omeprazole) are documented to impair the absorption of Cyanocobalamin (B12) by reducing gastric acid. Other substances like Colchicine and Para-aminosalicylic acid are also noted to impair B12 absorption.
  • Substance Constraints: Heavy or chronic alcohol intake is documented to impair the absorption of both Folic acid and Cyanocobalamin. An administration timing rule exists for oral B12: the ingestion of large amounts of Ascorbic acid (Vitamin C) must be separated by at least one hour due to potential B12 destruction.

These interactions are formally documented in government regulatory sources and define how the components of Angiovit interact with specific medications and substances.

Mechanism of Action

How Angiovit Works: Pharmacodynamic Mechanism

Angiovit functions as a metabolic agent, providing the three essential B-vitamin cofactors ( B6, B9, B12) required to activate key enzymes that govern homocysteine metabolism.

Dual-Pathway Regulation of Homocysteine Metabolism

This mechanism is defined by the supply of coenzymes that enable two complementary processes. B9 and B12 synergistically facilitate the activity of Methionine Synthase ( MS) in the remethylation pathway. Simultaneously, B6 catalyzes the function of Cystathionine beta-Synthase ( CBS) in the transsulfuration pathway. This dual action promotes the efficient catabolism of homocysteine.

Modulation of Vascular Endothelial Integrity

This downstream mechanistic cascade links molecular action to systemic physiological effect. By accelerating the enzymatic clearance of homocysteine, the drug reduces the concentration of this metabolite in the bloodstream, limiting the oxidative stress it places on the endothelial lining of blood vessels. This sustained metabolic detoxification contributes to the preservation of endothelial integrity. The combination is necessary for optimal regulation of the homocysteine load, as a deficiency in any one cofactor constrains the overall enzymatic activity.

Dosage and Administration Information

How to Use Angiovit: Official Administration Guidelines

This section outlines the instructions for the proper use of Angiovit (a B-vitamin complex).


Administration Scope

Parameter Instruction
Route of Administration Oral (by mouth).
Dosing Schedule The standard regimen for adults is one tablet per day.
Timing in Relation to Meals May be taken with or immediately after a meal to aid absorption and reduce potential gastrointestinal upset.
Preparation Requirements No preparation (e.g., dilution or reconstitution) is required.
Special Procedural Conditions The tablet must be swallowed whole. It should not be crushed, split, or chewed, as this may affect the integrity of the dose.

Usage Protocol

Classification Detail
Administration Method Type Oral tablet.
Frequency Pattern Once daily (a fixed daily regimen).
Duration of Course The length of the treatment course is determined by the prescribing healthcare professional, often based on the periodic monitoring of blood parameters.

Procedural Summary

Official Step Sequence:

  • Take the prescribed dose of one Angiovit tablet once daily.
  • Swallow the tablet intact using a liquid (e.g., water).
  • Maintain the consistent, daily schedule for the prescribed duration of therapy.

Connection to the overall use protocol: The administration protocol involves a consistent and non-manipulative method. The procedural structure mandates the oral intake of a single, whole tablet daily, establishing a simple, continuous dosing regimen that requires no special preparation steps outside of standard swallowing.

Recent Clinical Evidence

This summary describes the types of scientific research that have evaluated the B-vitamin combination (Folic acid, Pyridoxine, and Cyanocobalamin) in Angiovit, focusing only on the structure and findings of the studies, without providing clinical advice or treatment recommendations.


Evidence for Metabolic Correction and the Homocysteine Biomarker

Research consistently explores the B-vitamin combination in relation to the plasma homocysteine levels (a biomarker). Numerous Randomized Controlled Trials (RCTs) and subsequent meta-analyses consistently reported measurements of a change in this biomarker following supplementation. However, long-term outcomes related to this metabolic effect are not fully established, and whether the biomarker shift corresponds to major clinical health outcomes remains uncertain.

Evidence for Cardiovascular Risk and Major Vascular Events

Large-scale clinical research programs were conducted to examine whether B-vitamin supplementation was associated with changes in serious clinical outcomes, such as rates of stroke and myocardial infarction (heart attack). Findings were mixed when evaluating heart events. Some meta-analyses reported patterns indicating an association with the incidence of stroke in certain populations.

Differences in Findings Across Key Clinical Endpoints

The data reported less uniformity for major clinical events compared to the highly observed metabolic outcome (homocysteine). The evidence does not always translate directly into a consistent observation of changes in the rates of myocardial infarction events.

Evidence for Cognitive Function and Brain Health

Research has explored the potential relationship between B-vitamin supplementation and outcomes related to cognitive function in older adults. Evidence in this domain was reported as limited and heterogeneous. The certainty remains low because sample sizes were limited in some research.

Long-Term Studies and Follow-Up Duration

Major B-vitamin trials required long-term follow-up, observing participants over a period of three to seven years to capture clinical events. However, there is limited information for long-term outcomes regarding the absolute durability of the metabolic effect after supplementation ceases.

Evidence in Special Populations

Research also examined the combination in patients with chronic comorbidities, such as Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus. Findings apply only to the populations studied, and data for certain groups (such as children) remain insufficient.

What is Still Uncertain About the Research

Research provides context but not individual predictions. The primary uncertainty lies in whether the observed biomarker change consistently corresponds to an observable pattern in the rates of major clinical outcomes. Key limitations include limited follow-up durations in many cognitive studies and varying data quality across studies.

Key Studies & References

  1. Role of vitamin B12 and folic acid in treatment of Alzheimer's disease: a meta-analysis of randomized control trials

Frequently Asked Questions (FAQ)

Common questions about Angiovit (FAQ)

Q: What exactly is Angiovit used for besides general heart health?

According to official product information, the B-vitamins in Angiovit (B6, B9, B12) are vital for more than just vascular support. They are essential cofactors required for key bodily processes, including red blood cell formation, DNA synthesis, and the proper function of the central nervous system, in addition to supporting homocysteine metabolism.


Q: Why do doctors recommend Angiovit for people trying to conceive?

The Folic acid (Vitamin B9) component is widely recognized by health authorities for its essential role in preventing certain birth defects, specifically neural tube defects, when taken around the time of conception. While Angiovit's use during pregnancy is permitted, any decision regarding pre-conception or prenatal supplementation should be reviewed by a qualified healthcare professional.


Q: What is the difference between Angiovit and a standard B vitamin complex?

Angiovit is classified as a combination product that contains specific, high-dose amounts of only three B vitamins: Folic acid (B9), Pyridoxine (B6), and Cyanocobalamin (B12). It is specifically formulated and indicated to support the metabolism of homocysteine. A standard B vitamin complex typically contains a wider, less targeted range of B vitamins and sometimes other minerals.


Q: Does Angiovit help with nerve problems or just circulation?

While the primary indication is for metabolic and vascular support, the Vitamin B12 (Cyanocobalamin) component is necessary for myelin synthesis and normal nerve function. However, regulatory documents warn that high intake of Vitamin B6 over long periods is associated with a risk of peripheral neuropathy (tingling or numbness). This highlights the importance of adherence to prescribed use to help manage this risk.


Q: Are there specific food groups I should avoid while taking Angiovit?

Official regulatory documents do not restrict general food groups. However, they specifically advise that heavy or chronic alcohol intake can impair the absorption of the Folic acid and B12 components. Also, taking large amounts of Ascorbic acid (Vitamin C) should be separated from oral B12 ingestion by at least one hour to prevent potential destruction of the B12.


Q: Can Angiovit be taken by someone who is generally healthy, as a preventative measure?

The official indication for Angiovit is typically for the prevention or correction of specific B-vitamin deficiencies and for supporting metabolic health, such as the management of high homocysteine levels. It is generally not labelled for routine use by people who are healthy and may not be experiencing the specific metabolic need for which the product is indicated.


Q: Why do some people report feeling nauseous after starting Angiovit?

The official regulatory safety documentation lists mild transient diarrhea as a documented common side effect. Although nausea is a frequent experience reported by users of oral vitamin supplements, it is not explicitly listed in the official adverse reactions for this specific B-vitamin combination.


Q: Can children or adolescents safely take Angiovit?

The use of Angiovit is not recommended or is contraindicated for children under 3 years of age. Official eligibility is generally restricted to adults and adolescents (ge 18 years of age) who require supplementation. Decisions regarding use for individuals outside of these specified age groups are typically made by a healthcare professional.


Q: Can men take Angiovit for the same reasons women do?

Yes, official regulatory documents defining eligibility for use are based on age and clinical condition, such as B-vitamin deficiency or elevated homocysteine levels. The lack of gender-based restrictions means the product may be used by both men and women who meet the indications.


Q: Is it possible to take too many B vitamins when also taking Angiovit?

Yes, it is possible to take too much of some B vitamins. Regulatory text specifically warns that high doses or long-term intakes of the Pyridoxine (B6) component are associated with the risk of developing peripheral neuropathy (tingling or numbness). It is important that total B vitamin intake from all sources be reviewed by a healthcare professional.


Q: Are the side effects of Angiovit more likely at higher doses?

Yes, for certain risks, the likelihood is dependent on the amount taken over time. The serious neurological effect of peripheral neuropathy is explicitly associated with long-term intakes or high doses of Pyridoxine (B6). This indicates a dose- and duration-dependent pattern for at least one critical safety concern.


Q: Can people with kidney issues safely use Angiovit?

The B-vitamins in this product are water-soluble and processed by the kidneys. While the combination has been studied in populations with Chronic Kidney Disease (CKD), the regulatory label does not provide a universal safety statement or contraindication. For individuals with kidney issues, use requires specific professional evaluation and management.


Q: Can Angiovit interact with herbal supplements like St. John's Wort?

Official regulatory documents list specific interactions with certain pharmaceutical drugs and substances like alcohol or Vitamin C. However, they do not typically include herbal supplements in the formal Interaction Profile. As with any medication, any use alongside herbal intake should be reviewed by a healthcare professional.


Q: Has Angiovit been studied in relation to improving cognitive function?

Research has explored the potential relationship between B-vitamin supplementation and outcomes related to cognitive function in older adults. Official summaries report that the evidence in this domain is limited and heterogeneous, and the certainty of findings remains low.


Q: How long is a typical course of treatment with Angiovit?

The official product information states that the duration of therapy is not a fixed time period. The length of the treatment course is determined individually by the prescribing healthcare professional, often based on the periodic monitoring of relevant blood parameters, such as homocysteine levels.


Q: Can taking Angiovit cause changes to my sleep patterns or energy level?

Official regulatory safety documentation does not list changes to sleep patterns or energy levels as reported side effects. While the B12 component is essential for red blood cell formation and nervous system health, which can affect energy, any changes are not documented as direct adverse reactions in the safety profile.


Q: Does Angiovit contain any common allergens like gluten or lactose?

Regulatory labeling requires full disclosure of all components, including inactive ingredients (excipients). It is necessary to review the full ingredient list found in the product packaging or official patient information leaflet to check for confirmed sensitivities.


Q: Is it normal to experience a metallic taste when taking this medication?

A metallic taste is not listed among the official adverse reactions (which include mild diarrhea and rash). This type of sensory change is sometimes associated with other supplements or deficiencies, but it is not a documented side effect of this specific B-vitamin combination.


Q: How does Angiovit compare to medications focused solely on cholesterol lowering?

Angiovit's mechanism is focused on clearing the metabolite homocysteine, which is linked to vascular health. However, the regulatory text does not provide a direct comparison or statement of equivalence to specific lipid-lowering medications (like statins) that focus on cholesterol. Angiovit is a vitamin complex and not a substitute for cholesterol management drugs.

How should Angiovit be stored and disposed of?

Angiovit tablets must be stored according to regulatory standards to maintain the stability of the B-vitamins ( B6, B9, B12).

Storage Requirements

Scope Element Official Regulatory Requirement
Temperature: Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Protection: Must be protected from light, moisture, and excessive heat.
Handling: Do not freeze. Keep in the original container and keep the container tightly closed.
Safety: Must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Angiovit tablets should not be flushed down the toilet or poured into any drain. Patients are required to consult with a pharmacist or a local waste disposal service for guidance on approved methods for discarding the product in accordance with pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Angiovit found in:

A-Z Index: